GlassScriptPhysician profile
Brooke D Vincent
NPI 1457583874
$4,217.95
in general payments reported to CMS, 2019-2025
22 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $907 · 2022: $774 · 2023: $1,734 · 2024: $484 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574 · Travel and Lodging: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,573.92 |
| Travel and Lodging | $963.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $1,259.08 | 2022-2023 | Ha Minuteman G3-R |
| Collegium Pharmaceutical, INC. | $834.06 | 2021-2025 | Xtampza, Belbuca |
| Boston Scientific Corporation | $301.83 | 2021-2023 | Superion Indirect Decompression System |
| Ibsa Pharma INC. | $274.19 | 2021-2023 | Tirosint, Licart |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $250.69 | 2021-2024 | Relistor |
| Medtronic, INC. | $237.87 | 2021-2024 | Intellis Adaptivestim |
| Almatica Pharma LLC | $233.10 | 2021-2023 | Gralise |
| Abbott Laboratories | $131.16 | 2021 | |
| Tersera Therapeutics LLC | $85.05 | 2021-2025 | Prialt |
| Nalu Medical, INC. | $84.82 | 2021-2024 | Nalu Neurostimulation System |
| Saluda Medical Americas, INC. | $81.97 | 2025 | Evoke |
| Vertos Medical, INC. | $77.11 | 2024 | Mild Device Kit |
| Redhill Biopharma INC. | $74.74 | 2021-2022 | |
| Si-Bone, INC. | $65.22 | 2024 | |
| Biodelivery Sciences International, INC. | $55.67 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $52.25 | 2022 | |
| Virtus Pharmaceuticals LLC | $28.03 | 2025 | Levorphanol Tartrate |
| Azurity Pharmaceuticals, INC. | $22.06 | 2023 | Horizant |
| Bioventus LLC | $21.63 | 2022 | |
| Grt US Holding, INC. | $18.27 | 2021 | |
| Curonix LLC | $14.93 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Vertex Pharmaceuticals Incorporated | $14.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Vincent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.